FTC and MD dispensing
Executive Summary
FTC reauthorization bill passes House Energy & Commerce Committee July 14 but is still pending at Rules Committee. Bill mandates that "the Commission only, and not the Commission staff," may intervene in rules or regulations of local, state or federal agencies. Introduced July 8, HR 2897 would halt the recent flow of opinions from FTC's Bureau of Competition -- without full commission backing -- to state legislatures in favor of physician dispensing. The bureau has written to three legislatures, most recently the California assembly ("The Pink Sheet" May 11, T&G-9).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.